Today, the Sr. VP of Operations of Hemispherx Biopharma Inc (HEB), Wayne Springate, bought shares of HEB for $21K.
This recent transaction increases Wayne Springate’s holding in the company by 150.56% to a total of $36.08K. In addition to Wayne Springate, 2 other HEB executives reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
Currently, Hemispherx Biopharma Inc has an average volume of 130.5K.
The insider sentiment on Hemispherx Biopharma Inc has been positive according to 24 insider trades in the past three months. This sentiment is higher than the average sentiment of company insiders in this sector.
Wayne Springate’s trades have generated a -16.4% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Hemispherx Biopharma, Inc. operates as a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and Ampligen.
